Phase II study of niraparib in patients with advanced melanoma with genetic homologous recombination (HR) mutation/alteration
TPS9596Background: There are a limited number of therapeutic options available for metastatic melanoma patients progressing on the checkpoint inhibitor(s) and BRAF-targeting drugs. PARP inhibitors have been approved in the setting of BRCA1/2 germline mutations, and have demonstrated activity in the...
Saved in:
| Published in | Journal of clinical oncology Vol. 41; no. 16_suppl; p. TPS9596 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | English |
| Published |
American Society of Clinical Oncology
01.06.2023
|
| Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!